The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2024 | Approaching patients with myeloma who progress on lenalidomide & daratumumab: challenges
Jesús San Miguel, MD, PhD, University of Navarra, Pamplona, Spain, discusses challenges in treating patients with multiple myeloma who progress on lenalidomide, emphasizing that patients may also become refractory to daratumumab. Prof. San Miguel highlights the need for new therapies and tailored treatment approaches to overcome this challenge. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
